title: Desensitization to lenograstim after a life- threatening reaction to filgrastim.
authors.forename: B
authors.initials: B
authors.lastname: Nuñez-Acevedo
authors.forename: B
authors.initials: B
authors.lastname: Rodríguez-Jiménez
authors.forename: J
authors.initials: J
authors.lastname: Domínguez-Ortega
authors.forename: E
authors.initials: E
authors.lastname: González-Montellano
authors.forename: N
authors.initials: N
authors.lastname: Ibáñez-Heras
authors.forename: S
authors.initials: S
authors.lastname: Enrech-Francés
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D003429:Cross Reactions; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D007108:Immune Tolerance; D007428:Intradermal Tests; D000078224:Lenograstim; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D011237:Predictive Value of Tests; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D000069585:Filgrastim